Cited by 172Endometriosis Research and TreatmentMicroRNA in disease regulationExtracellular vesicles in disease

Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis

Open access
Jia, S.-z., Yang, Y., Lang, J., Sun, P., Leng, J.·2013·Human Reproduction

Abstract

STUDY QUESTION: Can plasma microRNAs be used as a non-invasive diagnostic test for the detection of endometriosis? SUMMARY ANSWER: Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis compared with those without endometriosis in mainland China. WHAT IS KNOWN ALREADY: There is currently a pressing need to develop a non-invasive diagnostic test for endometriosis. Altered circulating microRNA profiles have already been linked to various disease states. STUDY DESIGN, SIZE, AND DURATION: This was a prospective laboratory study in a tertiary-referral university hospital in Beijing, PR China, between January 2012 and May 2012. Twenty-three women with histologically proven endometriosis and 23 endometriosis-free controls were enrolled in this study. PARTICIPANTS/MATERIALS, SETTING, AND METHODS: Laparoscopic inspection of the abdominopelvic cavity was performed for each patient, and peripheral blood samples were collected before laparoscopy. Microarray-based microRNA expression profiling was used to identify differentially expressed microRNAs in plasma samples between women with and without endometriosis, and quantification of selected microRNAs was performed using quantitative RT-PCR. MAIN RESULTS AND THE ROLE OF CHANCE: Twenty-seven microRNAs were differentially expressed between women with and without endometriosis, of which six microRNAs (miR-15b-5p, miR-17-5p, miR-20a, miR-21, miR-22 and miR-26a) were selected for validation. MiR-17-5p, miR-20a and miR-22 were significantly down-regulated in women with endometriosis compared with controls (P = 0.011, 0.0020 and 0.0002, respectively), yielding an area under the receiver operator characteristics curve of 0.74 [95% confidence interval (CI): 0.58-0.90], 0.79 (95% CI: 0.65-0.93) and 0.85 (95% CI: 0.71-0.98) in discriminating endometriosis from controls, respectively. LIMITATIONS AND REASONS FOR CAUTION: Our sample size was small and all cases were rAFS stage III-IV, which may limit generalization of plasma microRNAs for early diagnosis of endometriosis. Moreover, only six microRNAs were selected for validation. WIDER IMPLICATIONS OF THE FINDINGS: Plasma microRNAs provide a promising opportunity for detection of endometriosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humrep/des413

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Jia et al. demonstrated the applicability of circulating levels of miR-17-5p, miR-20a, and miR-22 in discriminating patients with severe endometriosis from control cohorts with an area under the curve value of 0.90.

    “Furthermore, Jia et al. demonstrated the applicability of the circulating level of miR-17-5p, miR-20a, and miR-22 in discriminating patients with severe endometriosis from control cohorts with an area under the curve value of 0.90 (110), further verifying the potential use of circulating miRNA as a diagnostic marker for endometriosis.”

    From Biomarkers in endometriosis: Challenges and opportunities (2017) · cites this paper as [110]

  • A limiting factor hindering the exploration of miRNA as biomarkers in clinical trials is the small sample sizes of patients and lack of representation of all stages of endometriosis, stratified by menstrual stage.

    “However, one limiting factor hindering the exploration of miRNA as biomarkers in clinical trials is the small sample sizes of patients and lack of representation of all stages of endometriosis, which are also stratified by menstrual stage (85, 109, 110).”

    From Biomarkers in endometriosis: Challenges and opportunities (2017) · cites this paper as [110]

  • Circulating and tissue miRNA have merit to be used as noninvasive or minimally invasive biomarkers for endometriosis, especially for severe cases.

    “Indeed, there is merit for the circulating and tissue miRNA to be used as noninvasive or minimally invasive biomarkers for endometriosis, especially for severe cases of endometriosis (110).”

    From Biomarkers in endometriosis: Challenges and opportunities (2017) · cites this paper as [110]

  • Reduced plasma levels of miR-17-5p, miR-20a, and miR-22 and elevated plasma levels of miR-16, miR-191, and miR-195 have been found in women with endometriosis compared with women without endometriosis.

    “Reduced plasma levels of miR-17-5p, miR-20a, and miR-22 [86] and elevated plasma levels of miR-16, miR-191, and miR-195 [87] have been found in women with endometriosis compared with women without endometriosis.”

    From Update on biomarkers for the detection of endometriosis (2015) · cites this paper as [86]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jia, S.-Z., Yang, Y., Lang, J., Sun, P., & Leng, J.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Leng, J.
Venue
Human Reproduction
Published
2012-11-30
Volume
28
Issue
2
Pages
322-330
ISSN
  • 0268-1161 (ISSN-L)
  • 1460-2350
OpenAlex
W2116069971
Cited by
172
References
64
Citations by year
2026: 3 · 2025: 18 · 2024: 10 · 2023: 14 · 2022: 15 · 2021: 19 · 2020: 23 · 2019: 12 · 2018: 13 · 2017: 6 · 2016: 12 · 2015: 11 · 2014: 10 · 2013: 5
FWCI
9.72
Type
journal article
Language
en
Open access
Locations
  • Human Reproduction (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81170548)
  • Chinese Academy of Medical Sciences
  • Peking Union Medical College Hospital
  • Peking Union Medical College
  • U.S. Public Health Service (5T76MC00001)
  • National Cancer Institute (CA50385, R01CA050385)
  • National Institute of Environmental Health Sciences (T32ES007069)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD52473, R01HD057210, HD48544, R01HD052473, R03HD048544, HD57210)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
endometriosis, plasma microRNA, miR-17-5p, miR-20a, miR-22, non-invasive diagnosis, circulating microRNA biomarkers, diagnostic accuracy, miR-15b-5p, miR-21, miR-26a, miRNA expression profiling, women's health, China
MeSH terms
Adult, Endometriosis, Female, Humans, Prospective Studies, Down-Regulation, Cluster Analysis, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, MicroRNAs, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review